Literature DB >> 7575681

The P-glycoprotein-mediated relative decrease in cytosolic free drug concentration is similar for several anthracyclines with varying lipophilicity.

H S Mülder1, H Dekker, H M Pinedo, J Lankelma.   

Abstract

We have used a new methodology to measure the activity of P-glycoprotein (P-gp) in multidrug-resistant (MDR) tumor cells. This activity leads to a lower cytosolic concentration and a lower cytotoxicity of the classical anthracyclines, daunorubicin (DNR), and doxorubicin (DOX). It has been reported that the anthracycline idarubicin (IDA), which is more lipophilic, has a higher clinical efficacy in acute myeloid leukemias (AML) than DNR and DOX. In our study, the aim was to determine for a series of anthracyclines how variations in the passive drug influx rate as well as the P-gp-mediated drug pumping rate affect their cytosolic free drug concentrations and how these parameters are related to drug cytotoxicity. We selected six anthracyclines: DOX, DNR, epidoxorubicin (EPI), IDA, cyano-morpholino-doxorubicin (CMD), and carminomycin (CAR), ordered according to their increasing octanol/PBS buffer concentration ratios, respectively. To measure the passive permeation coefficient, the P-gp-mediated drug pumping rate, and the cytosolic free drug concentration, we used a flow-through system in which cells were exposed to a flowing medium containing drugs. We used the MDR P-gp-containing cell line KB8-5. It was shown that the passive drug permeation coefficient as well as the drug pumping rate of P-gp increased with increasing lipophilicity in this series of anthracyclines. The cytosolic free drug concentration was lowered by P-gp to a similar extent in KB8-5 cells for all drugs tested (40-50% of the extracellular drug concentration). CMD, IDA, and CAR had lower IC50 values and lower resistance factors in comparison to DOX, DNR, and EPI. Verapamil reversed the resistance for all anthracyclines tested. In conclusion, for several anthracyclines the activity of P-gp leads to a similar relative decrease in the cytosolic free drug concentration; consequently, the reported lower resistance factor of IDA compared to that of DNR is not due to the inability of P-gp to export IDA from cells.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575681     DOI: 10.1016/0006-2952(95)00221-k

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  5 in total

1.  Anticancer Drug-Phospholipid Conjugate for Enhancement of Intracellular Drug Delivery.

Authors:  Taewon Hwang; Hee Dong Han; Chung Kil Song; Hasoo Seong; Jung Hyun Kim; Xiaoyuan Chen; Byung Cheol Shin
Journal:  Macromol Symp       Date:  2007-04-01

2.  Analysis of the interaction of induction regimens with p-glycoprotein expression in patients with acute myeloid leukaemia: results from the MRC AML15 trial.

Authors:  M Pallis; R Hills; P White; M Grundy; N Russell; A Burnett
Journal:  Blood Cancer J       Date:  2011-06-17       Impact factor: 11.037

3.  Human hepatoma cells rich in P-glycoprotein are sensitive to aclarubicin and resistant to three other anthracyclines.

Authors:  G Lehne; P De Angelis; O P Clausen; H E Rugstad
Journal:  Br J Cancer       Date:  1996-12       Impact factor: 7.640

4.  Cytotoxic effect of the cyclosporin PSC 833 in multidrug-resistant leukaemia cells with increased expression of P-glycoprotein.

Authors:  G Lehne; H E Rugstad
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

5.  Polymeric micelles, a promising drug delivery system to enhance bioavailability of poorly water-soluble drugs.

Authors:  Wei Xu; Peixue Ling; Tianmin Zhang
Journal:  J Drug Deliv       Date:  2013-06-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.